Pfizer Inc. (NYSE:PFE) Position Increased by Duncan Williams Asset Management LLC

Duncan Williams Asset Management LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 39.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 15,623 shares of the biopharmaceutical company’s stock after acquiring an additional 4,416 shares during the period. Duncan Williams Asset Management LLC’s holdings in Pfizer were worth $414,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. AQR Capital Management LLC raised its holdings in shares of Pfizer by 1.6% during the second quarter. AQR Capital Management LLC now owns 612,429 shares of the biopharmaceutical company’s stock valued at $17,068,000 after acquiring an additional 9,435 shares during the period. Raab & Moskowitz Asset Management LLC increased its holdings in shares of Pfizer by 52.7% in the 2nd quarter. Raab & Moskowitz Asset Management LLC now owns 238,937 shares of the biopharmaceutical company’s stock valued at $6,685,000 after purchasing an additional 82,497 shares during the period. MidWestOne Financial Group Inc. lifted its position in shares of Pfizer by 1.5% in the second quarter. MidWestOne Financial Group Inc. now owns 26,530 shares of the biopharmaceutical company’s stock worth $742,000 after purchasing an additional 386 shares in the last quarter. Straight Path Wealth Management boosted its holdings in shares of Pfizer by 21.3% during the second quarter. Straight Path Wealth Management now owns 37,025 shares of the biopharmaceutical company’s stock worth $1,036,000 after purchasing an additional 6,513 shares during the period. Finally, Ascent Group LLC lifted its position in Pfizer by 23.2% in the 2nd quarter. Ascent Group LLC now owns 50,845 shares of the biopharmaceutical company’s stock worth $1,423,000 after buying an additional 9,565 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Down 1.3 %

Shares of PFE opened at $26.10 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a 50-day simple moving average of $26.11 and a 200-day simple moving average of $27.94. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The firm has a market capitalization of $147.89 billion, a P/E ratio of 35.27, a P/E/G ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. Pfizer’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.17) EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.59%. The ex-dividend date is Friday, January 24th. Pfizer’s payout ratio is 227.03%.

Insider Activity at Pfizer

In related news, Director Scott Gottlieb acquired 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 11.11 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of research reports. Sanford C. Bernstein initiated coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target on the stock. Guggenheim reduced their price target on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Wolfe Research began coverage on shares of Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective on the stock. Truist Financial decreased their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.